Evidence map›Paper›PMID 41335135›Full record

ReviewClinical and experimental medicine2025

Cuproptosis in lung cancer: a nexus of ncRNA regulation, epigenetics, and tumor microenvironment Remodeling.

Mohamed S Imam, Randa M Abdel-Sattar, Nasser M Aldekhail, Norah Khalid Abdullah Humaish, Shoug Abdulaziz Gary Gary, Mansour Abdulrahman Mansour Alkhulaifi, Misk Abdullah Mohammed Alqahtani, Malak Lafi Zaid Aldajani, Hasna Mohammed Jarallah Altuwayhir, Wasan Izzualdien Abdulrahman Alnaim and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mohamed S ImamDepartment of Clinical Pharmacy, National Cancer Institute, Cairo University, Fom El Khalig Square, Kasr Al-Aini Street, Cairo, 11796, Egypt. imammohamed311@gmail.com.
Randa M Abdel-SattarDepartment of Pharmaceutics, College of Pharmacy, Shaqra University, 11961, Shaqra, Saudi Arabia.
Nasser M AldekhailDepartment of Pharmacy, College of Pharmacy, Nursing and Medical Sciences, Riyadh Elm University, Riyadh, Saudi Arabia.
Norah Khalid Abdullah HumaishCollege of Pharmacy, Taif University, 21944, Taif, Saudi Arabia.
Shoug Abdulaziz Gary GaryCollege of Pharmacy, Taif University, 21944, Taif, Saudi Arabia.
Mansour Abdulrahman Mansour AlkhulaifiCollege of Pharmacy, Taif University, 21944, Taif, Saudi Arabia.
Misk Abdullah Mohammed AlqahtaniCollege of Pharmacy, Taif University, 21944, Taif, Saudi Arabia.
Malak Lafi Zaid AldajaniCollege of Pharmacy, Taif University, 21944, Taif, Saudi Arabia.
Hasna Mohammed Jarallah AltuwayhirCollege of Public Health and Health Informatics, University of Ha'il, 55476, Ha'il, Saudi Arabia.
Wasan Izzualdien Abdulrahman AlnaimCollege of Clinical Pharmacy, King Faisal University, Al-Ahsa, Eastern Province, Saudi Arabia.
Aldanah Hmoud AlotaibiCollege of Pharmacy, Shaqra University, 11961, Shaqra, Saudi Arabia.
Reem Jazzaa S AlotaibiCollege of Pharmacy, Shaqra University, 11961, Shaqra, Saudi Arabia.
Ahmed M MaylaVirology and Immunology Unit, Cancer Biology Department, National Cancer Institute (NCI), Cairo University, Cairo, 11796, Egypt.
Yasser Mabrouk BakrNational Cancer Institute, Cairo University, Fom El Khalig Square, Kasr Al-Aini Street, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains a leading cause of cancer-related mortality worldwide. Cuproptosis, a new form of programmed cell death, is emerging as a key regulator in tumor progression. In this review, we talk about the interplay between cuproptosis, non-coding RNAs (ncRNAs), and epigenetic modifications in lung cancer. We performed an extensive review of recent literature to explore the function of ncRNAs in the regulation of cuproptosis, their effects on tumor microenvironment remodeling, immune response regulation, and drug sensitivity. ncRNAs were found to modulate cuproptosis by influencing copper metabolism, apoptosis, and oxidative stress response. Specific ncRNA signatures possess prognostic biomarker and therapeutic target potential in lung cancer. In addition, ncRNA-mediated epigenetic regulation has significant influence on deciding lung cancer formation and treatment outcome. The integration of non-coding RNAs related to cuproptosis into therapies offers great promise for the improvement of lung cancer prognosis. Further studies are needed to validate these findings and promote their implementation in clinical practice.

Indexed as

CopperEpigenesis, GeneticLung NeoplasmsRNA, UntranslatedTumor MicroenvironmentAnimalsApoptosisGene Expression Regulation, NeoplasticHumansCopperRNA, UntranslatedBiomarkersCuproptosisEpigeneticsLung cancerNon-coding RNAsTargeted therapyTumor microenvironment

Identifiers

PMID41335135
PMCPMC12675717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.